Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome.

AIM: The present study was designed to examine the relationship between Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene (PPAR-gamma) and clinical and hormonal characteristics in women with polycystic ovary syndrome (PCOS). MATERIALS AND METHODS: One hundred patients with PCOS and 100 healthy subjects were included in the study. Serum levels of sex steroids were measured. Insulin resistance was evaluated by homeostasis model assessment (HOMA). The responses of glucose and insulin to an oral glucose tolerance test were analyzed by calculating the respective area under the curve (AUC) by the trapezoidal method. We used the restriction fragment length polymorphism technique and polymerase chain reaction to examine Pro12Ala polymorphism in exon 2 of PPAR-gamma. RESULTS: Pro12Ala polymorphism of PPAR-gamma was significantly elevated in control subjects (22%) compared with PCOS subjects (15%). All of the Pro12Ala polymorphisms of PPAR-gamma were heterozygous. When PCOS subjects with the Pro allele and the Ala allele of PPAR-gamma were compared, the latter had lower free testosterone, androstenedione, dehydroepiandrosterone sulfate, insulin and C-peptide levels, as well as lower luteinizing hormone/follicle-stimulating hormone ratio, HOMA insulin resistance index, AUCinsulin, Ferriman-Gallwey score, acne, body mass index and waist-to-hip ratio. CONCLUSION: We suggest that Pro12Ala polymorphism of the PPAR-gamma gene may be a modifier of insulin resistance in women with PCOS.     

Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in first-degree relatives of subjects with polycystic ovary syndrome.

AIM: This study was designed to examine the relationship between the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) gene and insulin resistance (IR) in first-degree relatives of subjects with polycystic ovary syndrome (PCOS). MATERIALS AND METHODS: One hundred and twenty family members of 55 patients with PCOS and 80 unrelated healthy control subjects without a family history of diabetes or PCOS were studied. IR was assessed by homeostatic model assessment (HOMA-IR) and area under the curve (AUC) for insulin during an oral glucose tolerance test in subjects with normal glucose tolerance and controls. Genetic analysis of the PPAR-gamma gene Pro12Ala polymorphism was performed by restriction fragment length polymorphism. RESULTS: Fasting insulin, HOMA-IR and AUC insulin were significantly higher in first-degree relatives of PCOS subjects than in controls. A significantly different allele distribution of the Pro12Ala polymorphism of PPAR-gamma was observed between the two groups, with the frequency of the variant Ala isoform being significantly reduced in the first-degree relatives of PCOS subjects (10.8%, 13 subjects) compared with the control group (22.5%, 18 subjects). All Pro12Ala polymorphisms of the PPAR-gamma gene were heterozygous. Compared with first-degree relatives of PCOS subjects with the Pro12Pro polymorphism of PPAR-gamma, first-degree relatives of PCOS subjects with the Pro12Ala polymorphism had low fasting insulin, HOMA-IR and AUC insulin levels. The combined prevalence rate for impaired glucose tolerance, impaired fasting glucose and diabetes was 40% (16 subjects) in mothers and 52% (20 subjects) in fathers of PCOS women. CONCLUSION: Our findings suggest that Pro12Ala PPAR-gamma gene polymorphism may be protective against IR and might prevent the development of diabetes mellitus in the first-degree relatives of subjects with PCOS.     

The effects of hyaluronic acid vaginal gel on the vaginal epithelium of ovariectomized rats

Objective: The aim of this study was to evaluate plasma gamma-glutamyltransferase (GGT) in gestational diabetes mellitus (GDM) in pregnant women at oral glucose tolerance test (OGTT) and the diagnosis of GDM and to explore whether this activity is associated with metabolic parameters. Method: This prospective control study included 37 women with GDM and 42 women with normal glucose tolerance in pregnancy (control group). In the study group (GDM), blood was taken for analyzing 100?g OGTT from women who have abnormal 50?g glucose challenge test (GCT). Results: Compared with the controls, the GDM group had significantly higher mean values for serum fasting glucose, insulin, homeostasis model assessment-insulin resistance (HOMA-IR), triglyceride and GGT. Within the GDM group, GGT levels were only negatively correlated with high-density lipoprotein (r?=??0.41, p?=?0.01). GGT was determined to be an independent metabolic parameter for GDM. While performing analyses receiver operational curve analysis, GGT cutoff set was set at 16 IU/L, the sensitivity was calculated as 86%, and specificity was as 37%. Conclusion: The increase at GGT level is an independent risk factor for GDM and identified as high-risk women for diagnosis of GDM.     

孕妇及其子代过氧化物酶体增殖物激活受体γ~2基因型差异与妊娠期糖尿病发病的关系

目的 通过对妊娠期糖尿病(GDM)孕妇及其子代过氧化物酶体增殖物激活受体啦(PPARG2)基因的Pro12Ala单核苷酸多态性(SNP)差异分析,探讨母胎基因差异与GDM发病的关系.方法 选择2005年10月至2007年2月于复旦大学附属妇产科医院产科住院分娩的GDM孕妇55例及其新生儿40例为GDM组,正常健康孕妇173例及其新生儿50例为对照组.采用聚合酶链反应.高效变性液相色谱.核苷酸序列测定分析方法,检测两组孕妇及其子代的PPARG2基因Prol2AiaSNP(包括Pro和Ala等位基因、Pro/Pro、Pro/Ala和Ala/Ala基因型)的频率分布情况.采用酶化学法测定孕妇空腹血糖(FBS)、总胆固醇(TC)、甘油三酯(TG)、载脂蛋白A(APO-A)、高密度脂蛋白(HDL)和低密度脂蛋白(LDL)水平.结果 (1)GDM组及对照组孕妇均以Pro/Pro基因型为主(分别为94.6%及90.8%),两组子代Pro/Pro基因型频率(分别为95.0%及94.0%)比较,差异无统计学意义(P>0.05);GDM组孕妇与其子代Pro/Pro基因型频率比较,差异也无统计学意义(P>0.05).GDM组及对照组孕妇Pro/Ala基因型频率(分别为5.5%及9.2%)比较,差异无统计学意义(P>0.05);GDM组子代Ala等位基因频率(2.5%)与对照组子代(3.0%)比较,差异无统计学意义(P>0.05).(2)两组中Pro/Pro基因型与Pro/Ala基因型孕妇FBS、Tc、TG、APO-A、HDL、LDL水平比较,差异均无统计学意义(P>0.05).(3)将孕妇的基因型与其子代的基因型配对组成4种配对类型,分别是Pro/Pro孕妇与Pro/Pro子代、Pro/Ala孕妇与Pro/Ala子代、Pro/Pro孕妇与Pro/Ala子代、Pro/Ala孕妇与Pro/Pro子代;GDM组孕妇及其子代与对照组孕妇及其子代各基因型配对的构成比不同(P相似文献   

Use of oral glucose tolerance test in early pregnancy to predict late-onset gestational diabetes mellitus in high-risk women

AIM: To evaluate if any single plasma glucose level from the four values of the normal 100-g oral glucose tolerance test (OGTT) in early pregnancy (< or =20 weeks of gestation) could predict gestational diabetes mellitus (GDM) diagnosed from a second OGTT in late pregnancy (28-32 weeks). METHODS: Glucose levels of pregnant women at high-risk for GDM, who had had a normal early OGTT, and who underwent the second test in late pregnancy, were studied. Each of the four plasma glucose values of the early OGTT was determined for sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). The receiver operating characteristic curves of these four OGTT values were then constructed to find the optimal value to predict late-onset GDM. RESULTS: Of 193 pregnant women who had had a normal early OGTT, 154 also had a normal OGTT in late pregnancy while 39 had an abnormal test and were diagnosed with GDM. Among the four glucose values of the early OGTT, the 1-h value yielded the best diagnostic performance to predict late-onset GDM. The sensitivity, specificity, PPV, NPV, and area under the curve achieved from its optimal cutoff level of > or =155 mg/dL (8.6 mmol/L) were 89.7%, 64.3%, 38.9%, 96.1%, and 0.77, respectively. CONCLUSIONS: A 1-h glucose value > or =155 mg/dL at the early OGTT yielded the best diagnostic performance. However, the low specificity and PPV rendered it suboptimal to predict late-onset GDM. Nevertheless, a considerable number of high-risk women could avoid the second OGTT in late pregnancy due to its high sensitivity and NPV.     

Gestational diabetes mellitus in Chinese women.

OBJECTIVE: To determine whether foreign diagnostic criteria for the diagnosis of gestational diabetes mellitus (GDM) are suitable for Chinese pregnant women. METHODS: The study participants were 340 pregnant women receiving obstetric care at the Shanghai Jiaotong University-Affiliated Sixth People's Hospital in Shanghai, China. The normal-pregnancy group comprised 190 women with no risk factor for GDM and the high-risk pregnancy group comprised 150 women who had at least one high-risk factor for GDM. All women took the diagnostic 100-g, 3-h oral glucose tolerance test (100-g 3-h OGTT) between 24 and 28 weeks of pregnancy. The results of the 100-g 3-h OGTT were classified according to three different sets of diagnostic criteria: (1) new, "Chinese" diagnostic criteria based on the results from the 100-g 3-h OGTT performed in the 190 healthy participating women; (2) the Carpenter and Coustan criteria; and (3) the National Diabetes Data Group (NDDG) criteria. Venous plasma glucose (VPG) was measured by the glucose oxidase method. A consistency check was used for analysis. Obstetric and neonatal outcomes were recorded. RESULTS: With 97.5% as the statistical cutoff value for the 100-g 3-h OGTT, the new diagnostic criteria for this study, based on data obtained from the 100-g 3-h OGTT performed on the 190 participating healthy pregnant women, were 5.2, 10.3, 8.9, and 7.7 mmol/L at 0, 60, 120, and 180 min. The e value was 0.83 for the new criteria vs. the Carpenter and Coustan criteria (P<0.001) and 0.70 for the new criteria vs. the NDDG criteria (P<0.001). In women with GDM and gestational-impaired glucose tolerance (GIGT), the incidence rates of macrosomia by the new criteria and the Carpenter and Coustan criteria were similar, but higher than the rates calculated with the NDDG criteria (P<0.05). CONCLUSION: With venous plasma glucose level measured by the glucose oxidase method, the Carpenter and Coustan criteria are applicable to Chinese pregnant women for diagnosis of GDM.     

妊娠期糖尿病75g OGTT不同时点血糖异常孕妇的临床特点与妊娠结局分析

目的:分析妊娠期糖尿病(GDM)75g葡萄糖耐量试验(75g OGTT)不同时点血糖异常孕妇的临床特点与妊娠结局。方法:选取2013年1月至2015年3月在华北理工大学附属医院行产前检查并住院分娩的妊娠期糖尿病孕妇150例,孕24~28周均直接行75g OGTT,检测结果中仅其中1项时点血糖异常为GDMⅠ组、2项时点血糖异常为GDMⅡ组、3项时点血糖均异常为GDMⅢ组。结果:(1)GDMⅢ组的孕前体重指数(BMI)高于GDMⅡ组和GDMⅠ组,两两比较差异均有统计学意义(P0.05);(2)GDMⅢ组的胰岛素使用率高于GDMⅡ组和GDMⅠ组(P0.05),GDMⅡ组与GDMⅠ组比较,差异无统计学意义(P0.05)。GDMⅢ组使用胰岛素的风险是GDMⅠ组的23.05倍(OR=23.05,95%CI 2.61~203.18);(3)GDMⅢ组的OGTT结果 3项时点血糖水平、FINS和胰岛素抵抗指数均高于GDMⅡ组和GDMⅠ组,两两比较差异均有统计学意义(P0.05);(4)GDMⅢ组的巨大儿发生率高于GDMⅡ组和GDMⅠ组(P0.05),GDMⅡ组与GDMⅠ组比较,差异无统计学意义(P0.05)。GDMⅢ组发生巨大儿的风险是GDMⅠ组的5.029倍(OR=5.029,95%CI 1.789~14.132)。结论:OGTT结果 3项时点均异常的GDM孕妇的孕前体重指数、胰岛素使用率、胰岛素抵抗水平均明显升高,也是发生巨大儿的高危人群。此类高危GDM孕妇临床应高度重视并积极干预。     

二次OGTT诊断妊娠期糖尿病围生结局分析

【摘 要】 目的：探讨二次口服葡萄糖耐量试验（oral glucose tolerance test,OGTT）诊断妊娠期糖尿病（gestational diabetes mellitus,GDM）的围生结局。方法：初次OGTT诊断GDM者188例,作为GDM1组。二次OGTT诊断GDM者38例,作为GDM2组;同期血糖正常产妇200例,作为对照组。比较3组产妇围生结局,如产后出血、早产、胎膜早破、巨大儿等。结果：GDM2组的产后出血、胎膜早破、大于胎龄儿发生率高于对照组,差异有统计学意义（P＜0.05）;GDM2组的巨大儿发生率高于GDM1组,差异有统计学意义（P＜0.05）。结论：二次OGTT可以提高GDM的诊断率,从而尽早诊断、积极干预GDM,改善妊娠结局。     

50gram oral glucose challenge test combined with risk factor-based screening for gestational diabetes

OBJECTIVE: Our aim was to study whether universal screening of all pregnant women by Oral Glucose Challenge Test (OGCT) would identify a higher number of women with Gestational Diabetes (GDM) than risk factor based screening. STUDY DESIGN: A 50 g OGCT test was performed prospectively in 532 unselected women at 26-28 weeks of gestation. The 1-h venous plasma glucose concentration of >7.3 mmol/l was considered as a positive screening result. Patients with a positive OGCT underwent a 75 g 2-h OGTT, which was used as the actual diagnostic test for GDM. When two or all three of the glucose concentrations in OGTT (measured at fasting state and 1 and 2 h after the 75 g glucose load) were above the 97.5th percentile the patient was considered as having GDM. In addition, women with risk factors for GDM also underwent a 75 g OGTT regardless of the result of the OGCT. RESULTS: A positive 50 g OGCT was obtained in 123 (23%) of the women. In 15 (12%) of these, a diagnosis of GDM was established by the subsequent OGTT. Out of the 409 remaining women with a normal OGCT, 148 (36%) had risk factors for GDM. An OGTT performed in these patients identified 4 additional women with a GDM. Seventy-nine percent of GDM was thus found with 50g OGCT without regarding risk factors. Forty-seven percent of the women with GDM would have been missed in screening by risk factors only. CONCLUSIONS: In our population 50 g OGCT appears to identify a higher number of GDM than risk factor based screening. Combined with risk factor screening a few more cases of GDM would be found.     

以妊娠预后评估妊娠期糖耐量受损异质性

目的 从妊娠预后角度，探讨不同时点妊娠期糖耐量受损（gestational impaired glucose tolerance，GIGT）之间是否存在异质性。方法 选取2000年至2006年在上海交通大学附属第一医院行50g糖筛查异常的孕妇1145例为研究对象，进行75g葡萄糖耐量试验，同时进行胰岛素释放试验，计算血糖曲线下面积及胰岛素敏感性指数，并随访至妊娠终止。比较1145例孕妇中，OGTT 1h异常（68例）及2h／3h异常（40例）两种糖耐量受损患者之间预后的差异，并与妊娠期糖尿病（gestational diabetes mellitus，GDM）患者（38g例）及糖代谢正常（normal glucose tolerance，NGT）孕妇（655例）进行比较。结果 1h GIGT孕妇巨大儿和新生儿低血糖发生率（10．29％和13．24％）与2h／3h糖耐量受损孕妇（5．00％和5．00％）及NGT患者（4．42％和4．73％）比较明显升高（P〈0．01），而2h／3h糖耐量受损孕妇巨大儿及新生儿低血糖发生率显著低于GDM组（11．26％和17．80％）（P〈0．01）。结论 妊娠期糖耐量受损孕妇存在异质性。     

MTNR1A and MTNR1B gene polymorphisms in women with gestational diabetes

Gestational diabetes mellitus (GDM) is glucose intolerance detected during pregnancy. The MTNR1B gene is the genetic locus associated with type 2 diabetes, that may affect insulin secretion and pancreatic glucose sensing. In this study, we examined the association between MTNR1A (rs2119882) and MTNR1B (rs10830963, rs4753426) gene polymorphisms and the risk of GDM. According to the results of their oral glucose tolerance test (OGTT), the women were divided into two groups: 204 pregnant women with GDM and 207 pregnant women with normal glucose tolerance (NGT). There were no statistically significant differences in the distribution of MTNR1A rs2119882 and MTNR1B rs4753426 genotypes and alleles between women with GDM and healthy pregnant women. With regard to the MTNR1B rs10830963 polymorphism, we observed a statistically significant prevalence of GG and CG genotypes and the G allele among pregnant women with GDM (GG?+?CG vs CC, OR 1.50, 95% CI 1.02–2.22, p?=?0.04; G vs C, OR 1.43, 95% CI 1.07–1.90, p?=?0.016). In a multivariate logistic regression analysis, a higher number of MTNR1B rs10830963?G alleles was an independent significant predictor of a higher risk of GDM. The results of our study indicate that MTNR1B rs10830963 polymorphism is associated with GDM susceptibility, and women with a higher number of G alleles have an increased risk of GDM development.     

Diagnosis of gestational diabetes mellitus using a modified 100 g oral glucose tolerance test.

OBJECTIVE: To determine an optimal cutoff level of a modified 100 g oral glucose tolerance test (OGTT) with its diagnostic performance for gestational diabetes mellitus (GDM). STUDY DESIGN: Obstetric records of 909 women who had undergone a 100 g OGTT were reviewed. A modified 100 g OGTT referred to a test using a summation of 1 and 2 h plasma glucose levels after 100 g glucose ingestion. The sensitivity and specificity of this summed glucose at various cutoff levels for diagnosing GDM were obtained. A receiver operating characteristic curve was then constructed to determine the optimal value for a GDM diagnosis. RESULT: Based on a conventional 100 g OGTT, GDM was detected in 155 women (17.1%). Using a modified 100 g OGTT, the optimal summed glucose value for GDM diagnosis was > or =341 mg 100 ml(-1) which yielded 93.5% sensitivity and 95.2% specificity. CONCLUSION: The modified 100 g OGTT demonstrated high diagnostic performance for GDM, with advantages over a conventional 100 g OGTT in terms of less time consuming, lower cost and fewer number of venipuncture.     

妊娠期糖耐量异常妇女胰岛功能与胰岛素抵抗的相关研究

目的:研究妊娠期糖耐量异常与胰岛β细胞功能、胰岛素抵抗等的关系。方法:对孕24~36周上海市孕妇共4568例(孕前有糖尿病或糖尿病家族史者排除),先行50g葡萄糖筛查试验,异常者再行75g口服葡萄糖耐量试验(OGTT)-胰岛素释放试验,选取OG-TT异常者318例作为试验组,OGTT正常者中随机选取320例作为对照组,获取各阶段的血糖值及血清胰岛素值,通过计算,用胰岛素敏感指数(ISI)、稳态评估模式、胰岛素储备能力/血糖最大升高值(ΔPI/ΔPG)了解胰岛β细胞功能及外周胰岛素抵抗情况。结果:OGTT异常组的OGTT后1h血清胰岛素(PI1)、胰岛素释放曲线下面积较OGTT正常组显著增高(P<0·05),而胰岛素敏感指数、ΔPI/ΔPG及HOMA-β细胞较OGTT正常组降低(P<0.05)。糖尿病(GDM)组与妊娠期糖耐量减退(GIGT)组相比:GDM组的BMI高于GIGT组,而胰岛素敏感指数、HOMA-β细胞低于GIGT组(P<0.05)。其它指标均无明显差异。结论:妊娠期糖耐量异常形成的主要原因为胰岛素抵抗而非胰岛分泌功能降低。     

An appropriate test for diagnosis of gestational diabetes mellitus

Early diagnosis of GDM is necessary to reduce maternal and fetal morbidity and mortality. As all approaches to diagnosis of GDM are costly and difficult, we meant to find an appropriate and simple way to perform this test. One-thousand six-hundred and fifty-three pregnant women were screened for GDM at 24–28 weeks of gestation. Initial screening was done by a glucose challenge test with 50?g glucose. If the 1-h blood glucose level exceeded 130 mg/dl, then a 3-h oral glucose tolerance test (OGTT) with 100?g glucose was performed, and diagnosis was established according to ADA criteria. For determining which plasma glucose level is the best test for diagnosis of GDM, we used receiver operative characteristic cures (ROC) by plotting sensitivity versus one minus specificity at different times of plasma glucose levels in OGTT. In 732 pregnant women with a positive GCT, a 2-h plasma glucose level above 150 mg/dl was the most powerful test for detecting GDM, which revealed a sensitivity and specificity of 0.84 (0.81–0.86) and 0.94 (CI: 0.92–0.96), respectively. The results of this study suggest that 2-h 100?g OGTT could be an appropriate approach to diagnose GDM, which is cost-effective and could reduce laboratory workload.     

早孕期空腹血浆血糖与妊娠期糖代谢异常的相关性

目的 探讨早孕期空腹血浆血糖(fasting plasma glucose,FPG)与妊娠期糖代谢异常的相关性.方法 选取2009年1月1日至2009年5月31日在北京大学第一医院妇产科产前保健及分娩的单胎非孕前糖尿病且早孕期5～13周检测FPG、资料齐全的孕妇656例,对其早孕期FPG孕24周后50 g葡萄糖负荷试验结果(glucose challenge test,GCT)、75 g葡萄糖耐量试验结果(oral glucose tolerance test,OGTT)、妊娠期糖尿病(gestational diabetes mellitus,GDM)和妊娠期糖耐量受损(gestational impaired glucose tolerance,GIGT)发病情况进行受试者工作特性(receiver operating characteristic,ROC)分析.结果 (1)早孕期FPG与孕24周后GCT的ROC分析:最大曲线下面积0.539,95%CI:0.493～0.586,两者无明显相关性(P=0.057).(2)早孕期FPG与孕24周后FPG异常的ROC分析:最大曲线下面积0.796(95%CI:0.672～0.920),如取5.05 mmol/L为界值,敏感性为54.5%,特异性为83.2%,两者存在相关性(r=0.432,P=0.000).(3)早孕期FPG与孕24周后OGTT 1、2、3 h血糖无相关性(r=0.093、0.036和0.107,P=0.122、0.549和0.074),OGTT服糖前与服糖后1、2、3 h血糖分别呈正相关(r=0.493、0.421和0.368,P均=0.000).(4)本研究中共656例早孕期孕妇的FPG值均＜6.1 mmol/L,诊断GDM 22例,GIGT 27例,早孕期FPG对预测最终发生GDM及GIGT无相关性.结论 早孕期FPG不能取代现有的50 g GCT作为孕期糖代谢异常的早期筛查指标,但早孕期FPG的检测是必要的.

Abstract：

Objective To investigate the relationship between early pregnancy fasting plasma glucose (FPG) and gestational glucose metabolism disorders. Methods Six hundred and fifty-six pregnant women who were singleton, non-diabetes before pregnancy and had FPG examined during 5-13 weeks of pregnancy were admitted into this study from January 1, 2009 to May 31, 2009. All these subjects had routine prenatal examination and finally delivered in the Department of Obstetrics of Peking University First Hospital. The FPG, 50 g glucose challenge test (GCT) after 24 weeks of pregnancy, 75 g oral glucose tolerance test (OGTT), gestational diabetes mellitus (GDM),gestational impaired glucose tolerance (GIGT) were analyzed with receiver operating characteristic (ROC) curve. Results (1) Relationship between FPG and GCT were analyzed with ROC curve.The maximum area under curve was 0. 539 (95% CI: 0. 493-0. 586) and there was no correlation between the FPG and GCT results(P=0. 057). (2) Relationship between early pregnancy FPG and abnormal FPG examined after 24 gestational weeks were also analyzed . The maximum area under curve was 0. 796(95% CI: 0. 672-0. 920). If 5. 05 mmol/L was taken as the cutoff value, the sensitivity and specificity was 54. 5% and 83. 2%, respectively. There was significant relationship between the two values (r=0. 432, P=0. 000). (3) There were no relationship between early pregnancy FPG and the blood glucose value of 1, 2 and 3 h in 75 g OGTT (r=0. 093, 0. 036 and 0. 107, P=0.122, 0. 549 and 0. 074 respectively). OGTT 0 h value was positively related to OGTT 1, 2 and3 h glucose level (r=0.493, 0.421 and 0.368, P=0.000, respectively). (4) All early pregnant FPG values in this study were under 6.1 mmol/L. Twenty-two GDM and 27 GIGT patients were diagnosed in this study. Early pregnancy FPG did not relate to the GDM and GIGT diagnosis.Conclusions Early pregnancy FPG could not replace 50 g GCT as an early screening for glucose metabolic abnormality in pregnancy, but FPG during early pregnancy is necessary.     

妊娠晚期超声检查异常再次行葡萄糖耐量试验结果分析

目的分析妊娠晚期因超声检查异常行75g葡萄糖耐量试验(OGTT)的结果及影响妊娠期糖尿病(GDM)诊断的因素。方法选择2010年9月至2011年1月间北京大学人民医院产科门诊,妊娠中期常规GDM筛查和诊断试验阴性,晚期因超声提示羊水过多和(或)胎儿大再次行75gOGTT的孕妇116例为研究对象,分为GDM组和非GDM组,对可能影响GDM诊断的因素进行统计学分析。结果诊断GDM19例(16.4%)。单因素分析提示年龄>30岁及常规筛查或诊断试验孕周<24周的孕妇GDM诊断阳性率高于年龄≤30岁和常规筛查或诊断试验孕周≥24周的孕妇(P<0.05)。多因素分析提示相对于年龄≤30岁的孕妇,>30岁的孕妇患GDM的OR>30(P<0.05);相对于超声检查时体质指数(BMI)较孕前增幅<4的孕妇,增幅>6的孕妇患GDM的OR=0.08(P<0.05),但增幅>6的孕妇超声检查孕周晚于增幅<4的孕妇(P<0.01)。结论对于妊娠中期常规筛查或诊断试验阴性的孕妇来说,妊娠晚期超声检查提示羊水过多和(或)胎儿大时,年龄>30岁的孕妇患GDM的可能性增加,超声检查时BMI较孕前增幅>6的孕妇可能性减少,但须考虑孕周的影响。     

Influence of medical nutrition therapy on borderline glucose intolerance in pregnant Taiwanese women

Objective: To investigate the influence of medical nutrition therapy (MNT) on borderline glucose intolerance (BGI) in pregnant Taiwanese women.

Methods: A total of 5194 singleton pregnant women were enrolled in this prospective, non-randomized study. The participants were subjected to the 50?g 1-h glucose challenge test (GCT) and 100?g 3-h oral glucose tolerance test (OGTT) to screening gestational diabetes mellitus (GDM). BGI was defined as a positive GCT and normal OGTT results. GDM was defined as a positive GCT and abnormal OGTT results. The women were categorized into the following groups: (1) GCT-negative, n?=?3881; (2) BGI with MNT, n?=?273; (3) BGI without MNT, n?=?712; and (4) GDM, n?=?328. Multiple logistic analyses were used to estimate the risks of pregnancy outcomes.

Results: The odds ratios (95% confidence interval) for total cesareans, third- or fourth-degree perineal lacerations, gestational hypertension or preeclampsia and macrosomia were 1.24 (1.04–1.49), 1.55 (1.06–1.28), 1.78 (1.21–2.61) and 2.50 (1.28–4.91) in the BGI without MNT group compared to the GCT-negative group. There was no difference between BGI with MNT and GCT-negative groups.

Conclusions: Women with BGI who did not receive MNT had increased risks of adverse pregnancy outcomes, whereas who received MNT had no different risk with GCT-negative women.     

妊娠期糖尿病产后糖代谢异常的危险因素

目的通过对妊娠期糖尿病(GDM)患者进行产后随访,回顾性分析影响GDM患者产后糖代谢变化的高危因素。方法收集2009年1月至2011年6月在河北省沧州市中心医院门诊产前检查并分娩的GDM患者236例,产后42d回访者158例,记录其孕前和孕期信息,包括:孕期年龄、身高、孕前体重、有否糖尿病家族史、孕期使用胰岛素情况、孕期并发症及合并症情况、新生儿出生时情况;并按OGTT试验结果分为研究组和对照组,进行高危因素筛查。结果研究组为60例糖耐量异常者,包括39例IGT/IFG患者和21例DM患者;对照组为98例糖耐量正常者,比较两组患者孕前、孕期和妊娠结局情况,结果可见高龄、糖尿病家族史、孕期应用胰岛素、合并子痫前期、早产是产后发生糖代谢异常的高危因素,差异有统计学意义(P<0.05)。结论存在高危因素的GDM患者产后糖代谢异常发生率较高,应针对性地对GDM患者进行产后临床筛查和随访。     

妊娠期糖代谢异常导致巨大儿发生的危险因素分析

目的:探讨妊娠期糖代谢异常导致巨大儿发生的相关危险因素,为降低巨大儿的出生率提供科学依据。方法:回顾性分析2007年1月至2009年4月上海市第六人民医院产科收治的妊娠期糖尿病(GDM)孕妇125例和妊娠期糖耐量减低(GIGT)孕妇21例的临床资料。根据是否分娩巨大儿分为两组,采用t检验、卡方检验和多因素Logistic回归分析巨大儿发生的相关危险因素。结果:①单因素分析提示:与非巨大儿组孕妇相比,巨大儿组孕妇的糖尿病家族史、曾分娩巨大儿史、孕前体重、孕期体重增加、空腹血糖水平、OGTT-1小时血糖水平等因素分布差异有统计学意义(P<0.05)。②Logistic多因素回归分析提示:空腹血糖水平升高、孕期体重增加、糖尿病家族史、分娩巨大儿史是巨大儿发生的主要危险因素。③空腹血糖≥5.3mmol/L的孕妇,随着血糖水平的升高,发生巨大儿的风险亦明显增加。结论:对妊娠期糖代谢异常孕妇,应加强其孕期体重和空腹血糖水平的监护和管理,以减少巨大儿的发生及改善相关不良妊娠结局。     

Can adiponectin predict gestational diabetes?

The aim of the present study was to evaluate whether adiponectin is a predictive factor for gestational diabetes mellitus (GDM) and is appropriate as a screening test for GDM. Three-hundred and fifty-nine women with singleton pregnancy and indications for GDM screening according to criteria of the American College of Obstetricians and Gynecologists were enrolled in the study between July 5, 2004 and March 11, 2005. After confirming gestational age (GA) and number of fetuses by ultrasound, all women underwent a 1-h glucose challenge test with 50 g glucose load (50-g GCT) between 21 and 27 weeks of GA. Blood samples for determination of adiponectin levels were also obtained on the same day. Subsequently, between 24 and 28 weeks of GA, the women underwent an oral glucose tolerance test with 100 g glucose load (100-g OGTT). The diagnosis of GDM was established when two or more of the following criteria were fulfilled: (1) fasting glucose >95 mg/dl; (2) 1-h glucose >180 mg/dl; (3) 2-h glucose >155 mg/dl; (4) 3-h glucose >140 mg/dl. Sixty women were diagnosed with GDM, a prevalence of 16.7%. There was no difference in age between the GDM and non-GDM groups. Pre-pregnancy and sampling-day body mass index (BMI), increase in weight and all blood glucose levels were greater in women with GDM than in those without (p < 0.05). Adiponectin concentrations were significantly negatively correlated with GA and plasma glucose levels of the GCT and each OGTT. Using logistic regression analyses, adiponectin, but not age, pre-pregnancy BMI and increase in weight, was demonstrated as an independent predictive factor for GDM. The area under the receiver-operator characteristic curve of adiponectin was significantly lower than that of the GCT [0.63 (95% confidence interval (CI) 0.53-0.67) vs. 0.73 (95% CI 0.71-0.80), p < 0.001]. At a cut-off value of 140 mg/dl of the 50-g GCT, the sensitivity and specificity of the test were 90% and 61%, respectively. The 50-g GCT could identify GDM in 54 (90%) out of 60 women. On the other hand, at an arbitrary cut-off value of 10 microg/ml for adiponectin, sensitivity of 91% and specificity of 31% were achieved. If this cut-off value was used for ruling in or out pregnant women for the GDM screening, 27% of all women could be eliminated from needing to perform an OGTT, with five women (8.3%) misclassified. In conclusion, this study demonstrated that adiponectin was an independent predictor for GDM. As for GDM screening, adiponectin was not as strong a predictor as GCT. However, with advantage of being less cumbersome, adiponectin could be used to rule out pregnant women at low risk of GDM.